Point72 Asset Management L.P. Boosts Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Point72 Asset Management L.P. grew its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 210.8% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 49,400 shares of the company’s stock after acquiring an additional 33,507 shares during the period. Point72 Asset Management L.P. owned about 0.18% of Establishment Labs worth $2,138,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ESTA. Hood River Capital Management LLC acquired a new stake in Establishment Labs during the 2nd quarter worth about $43,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Establishment Labs in the third quarter worth about $127,000. Nkcfo LLC acquired a new stake in Establishment Labs during the second quarter worth about $227,000. SG Americas Securities LLC purchased a new position in Establishment Labs during the second quarter valued at approximately $303,000. Finally, Black Swift Group LLC acquired a new position in Establishment Labs in the third quarter valued at approximately $312,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Establishment Labs Stock Performance

ESTA opened at $43.27 on Tuesday. The company has a market cap of $1.21 billion, a price-to-earnings ratio of -16.77 and a beta of 1.16. The firm’s fifty day simple moving average is $43.44 and its two-hundred day simple moving average is $44.26. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. Establishment Labs Holdings Inc. has a 52-week low of $22.05 and a 52-week high of $60.12.

Wall Street Analyst Weigh In

ESTA has been the topic of a number of analyst reports. Stephens raised shares of Establishment Labs to a “strong-buy” rating in a research note on Monday, December 2nd. BTIG Research lifted their price objective on shares of Establishment Labs from $62.00 to $65.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Citigroup increased their target price on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $60.60.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.